Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn
by
Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal. The move bolsters Mankind Pharma’s position in the Indian women’s health and fertility drug market. The deal will also aid Mankind Pharma in providing access to high-barrier products in critical care leveraging complex research and development (R&D) tech platforms.
BSV, with more than five decades of expertise in biopharmaceuticals, has an established presence with its in-house developed recombinant and niche biologic products. The company’s branded product portfolio spans women’s health, fertility and critical care, with several leading brands in their respective therapy areas.
Mankind Pharma’s vice-chairman and managing director, Rajeev Juneja, said the acquisition is a key milestone for the company and will establish it as a leader in the Indian women’s health and fertility market. He also welcomed BSV’s more than 2,500 employees to the Mankind family and said they look forward to working together to make a positive impact on women’s health around the world. The acquisition includes BSV’s comprehensive portfolio in women’s health, covering the reproductive lifecycle from fertility to post-pregnancy. Its significant portfolio in the fertility segment will aid in scaling in both Indian and international markets, especially with the increasing penetration of in vitro fertilisation (IVF) treatments.
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/